# Data Sheet (Cat.No.T10765)

TargetMol

## Eragidomide

### Chemical Properties



CAS No. : 1860875-51-9

Formula: C22H18ClF2N3O4

Molecular Weight: 461.85

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

### Biological Description

| | |
|---|---|
| Description | Dicyclanil is an insect growth regulator with a chemical structure similar to that of cyclopromazine. |
| Targets(IC50) | Apoptosis,Ligand for E3 Ligase,Molecular Glues |
| In vitro | Eragidomide demonstrated potent antiproliferative activity in 10 of 11 cell lines (e.g. NB4, U937, KG-1, MOLM-13, HL60 cells)with much less effect on the cell viability of PBMCs and THLE-2. The antiproliferative effect of Eragidomide is associated with apoptosis induction in all tested AML cell lines except OCI-AML3[1]. |
| In vivo | In NOD/SCID mice, heterogeneous responses to the Eragidomide treatment (2.5mg/kg BID for 4 weeks) were observed. Of 35 AML samples tested, 16 were highly responsive to Eragidomide with >75% reduction of AML engraftment, 10 showed moderate response between 45% and 75% reductions, and 9 showed reductions of <25%. AML is clinically characterized by the accumulation of blasts that are impaired for differentiation and maturation. Eragidomide induced myeloid differentiation of AML blasts in the Eragidomide responders[3]. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 240 mg/mL (519.65 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.1652 mL | 10.826 mL | 21.6521 mL |
| 5 mM | 0.433 mL | 2.1652 mL | 4.3304 mL |
| 10 mM | 0.2165 mL | 1.0826 mL | 2.1652 mL |
| 50 mM | 0.0433 mL | 0.2165 mL | 0.433 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ellen Filvaroff, et al. Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies. WO2017120446A1.
Surka C, et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood. 2021 Feb 4;137(5):661-677.
Liqing Jin, et al. A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1,
Blood, Volume 134, Supplement 1, 2019, Page 3940.



Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481